Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients
oleh: Tiago Carvalheiro, Ana P. Lopes, Maarten van der Kroef, Beatriz Malvar-Fernandez, Carlos Rafael-Vidal, Anneline C. Hinrichs, Nila H. Servaas, Femke Bonte-Mineur, Marc R. Kok, Lorenzo Beretta, Maili Zimmermann, Wioleta Marut, Jose M. Pego-Reigosa, Timothy R. D. J. Radstake, Samuel Garcia
| Format: | Article |
|---|---|
| Diterbitkan: | MDPI AG 2020-12-01 |
Deskripsi
Angiopoietin-2 (Ang-2), a ligand of the tyrosine kinase receptor Tie2, is essential for vascular development and blood vessel stability and is also involved in monocyte activation. Here, we examined the role of Ang-2 on monocyte activation in patients with systemic sclerosis (SSc). Ang-2 levels were measured in serum and skin of healthy controls (HCs) and SSc patients by ELISA and array profiling, respectively. mRNA expression of <i>ANG2</i> was analyzed in monocytes, dermal fibroblasts, and human pulmonary arterial endothelial cells (HPAECs) by quantitative PCR. Monocytes were stimulated with Ang-2, or with serum from SSc patients in the presence of a Tie2 inhibitor or an anti-Ang2 neutralizing antibody. Interleukin (IL)-6 and IL-8 production was analyzed by ELISA. Ang-2 levels were elevated in the serum and skin of SSc patients compared to HCs. Importantly, serum Ang-2 levels correlated with clinical disease parameters, such as skin involvement. Lipopolysaccharide (LPS) LPS, R848, and interferon alpha2a (IFN-α) stimulation up-regulated the mRNA expression of <i>ANG2</i> in monocytes, dermal fibroblasts, and HPAECs. Finally, Ang-2 induced the production of IL-6 and IL-8 in monocytes of SSc patients, while the inhibition of Tie2 or the neutralization of Ang-2 reduced the production of both cytokines in HC monocytes stimulated with the serum of SSc patients. Therefore, Ang-2 induces inflammatory activation of SSc monocytes and neutralization of Ang-2 might be a promising therapeutic target in the treatment of SSc.